---
title: "Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291420150.md"
description: "A recent nonclinical study carried out at Stony Brook University contributes to the mounting evidence of effectiveness in various animal models of neuropathic pain. The study highlights the potential for treatment in this area, showcasing positive results in multiple animal models."
datetime: "2026-07-01T12:44:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291420150.md)
  - [en](https://longbridge.com/en/news/291420150.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291420150.md)
generator: "portal-rs"
---

# Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

A recent nonclinical study carried out at Stony Brook University contributes to the mounting evidence of effectiveness in various animal models of neuropathic pain. The study highlights the potential for treatment in this area, showcasing positive results in multiple animal models.

### Related Stocks

- [ARTL.US](https://longbridge.com/en/quote/ARTL.US.md)

## Related News & Research

- [Artelo Biosciences reports positive preclinical data for ART27.13 in paclitaxel-induced peripheral neuropathy model](https://longbridge.com/en/news/292495956.md)
- [Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports](https://longbridge.com/en/news/297596287.md)
- [13:27 ETPatients Representing the Power of Advanced Therapies to Take Center Stage at Emily Whitehead Foundation's 2026 Believe Ball](https://longbridge.com/en/news/297074492.md)
- [08:05 ETWisner Baum Named to Leadership in Federal Spinal Cord Stimulator Litigation](https://longbridge.com/en/news/297514089.md)
- [SRX Global buys senior secured debt in CERo Therapeutics Holdings](https://longbridge.com/en/news/297509635.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**